4.6 Article

Dopamine and cAMP regulated phosphoprotein MW 32 kDa is overexpressed in early stages of gastric tumorigenesis

Journal

SURGERY
Volume 148, Issue 2, Pages 354-363

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/j.surg.2010.05.011

Keywords

-

Categories

Funding

  1. National Cancer Institute [R01 CA93999, T32CA106183]
  2. GI SPORE [CA95103]

Ask authors/readers for more resources

Background. Gastric adenocarcinoma is a leading cause of cancer mortality. The role of dopamine and cAMP regulated phosphoprotein MW 32 kDa (DARPP-32) overexpression in the gastric tumor genesis cascade remains unclear Methods. The expression of DARP-32 in the multistep caranogenesis cascade was examined using immunohistochemistry analysis on 533 samples The contribution of DARPP-32 in cellular transformation and molecular signaling was investigated using NIH3T3, AGS, and SNU16 cells Results. The composite expression score (CES), calculated from immunostaining patterns, increased ignificantly from normal or gastritis to metaplasia, dysplasia, and adenocarcinoma (P < 001). In patients with normal stomach or gastritis and tumor samples, a 76% and 77% chance, respectively, was found (P < 001) that CES was higher in the tumor High median CES correlated with well- or moderately differentiated (P = .03) gastric adenocarcinomas. NIH3T3 cells transfected with DARPP-32 demonstrated increased levels of phospho-AKT and a 5-fold increase in the number of foci as compared ith the control (P =.02). DARPP-32 expression in AGS cells led to increased protein levels of phospho-AKT and BCL-2. For validation, the knockdown of endogenous DARPP-32 expression in,SNU16 cells using shRNA resulted in decreased levels of phospho-AKT phosphorylation and BCL-2 Conclusion. Our results suggest that DARPP-32 overexpression may participate in the transition to intestinal metaplasza and in the progression to neoplasia The ability of DARP-32 to transform NIH3T3 cells and to regulate AKT and BCL-2 underscores its possible oncogenic potential (Singer), 2010,148:354-63.)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available